<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-28343" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part indexed="no" book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Renal Cell Cancer(Archived)</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Garfield</surname>
            <given-names>Karen</given-names>
          </name>
          <aff>Mount Sinai Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>LaGrange</surname>
            <given-names>Chad A.</given-names>
          </name>
          <aff>University of Nebraska Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Karen Garfield declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Chad LaGrange declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>4</day>
          <month>10</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-28343.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Renal cell carcinomas (RCCs), which originate within the renal cortex, are responsible for 80% to 85% of all primary renal neoplasms. Transitional cell carcinomas, which originate in the renal pelvis, comprise approximately 8%. Other parenchymal epithelial tumors, such as oncocytomas, collecting duct tumors, angiomyolipomas, and renal sarcomas, occur infrequently. In children, nephroblastoma and Wilms tumor are common. Medullary renal carcinoma is a rare but aggressive form of renal cell cancer that seen in sickle cell disease. Other less common subtypes are clear cell, papillary, and chromophobe malignancies.<xref ref-type="bibr" rid="article-28343.r1">[1]</xref><xref ref-type="bibr" rid="article-28343.r2">[2]</xref><xref ref-type="bibr" rid="article-28343.r3">[3]</xref></p>
      </sec>
      <sec id="article-28343.s2" sec-type="Etiology">
        <title>Etiology</title>
        <p>The exact cause of RCC is unknown. The following factors increase a person's risk for renal cancer: older age, obesity, hypertension, chronic renal failure, dialysis treatment, polycystic kidney disease, African American race, sickle cell disease, and renal stones.<xref ref-type="bibr" rid="article-28343.r4">[4]</xref><xref ref-type="bibr" rid="article-28343.r5">[5]</xref></p>
        <p>The following hereditary diseases increase the risk of RCC: tuberous sclerosis, Von Hippel-Lindau syndrome&#x000a0; Birt-Hogg-Dube syndrome, hereditary papillary renal carcinoma, and hereditary leiomyomatosis and renal cell carcinoma (HLRCC).</p>
        <p>Many studies have suggested that workplace exposure to certain substances increases the risk of RCC. Some of these substances are cadmium, herbicides, asbestos, and trichloroethylene.</p>
      </sec>
      <sec id="article-28343.s3" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>RCC is the most common type of kidney cancer in adults. It occurs most often in men ages 50 to 70.</p>
        <p>Globally, the incidence of RCC varies, with the highest rates observed in the Czech Republic and North America. In the United States, there are approximately 63,000 new cases and almost 14,000 deaths each year.</p>
        <p>In the United States, incidence rates of RCC have been on the rise through the mid-2000s. Most of the increases since the 1980s occurred in early-stage tumors.<xref ref-type="bibr" rid="article-28343.r6">[6]</xref></p>
      </sec>
      <sec id="article-28343.s4" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The proximal renal tubular epithelium is the kidney tissue from which RCC arises. The two forms are sporadic: nonhereditary and hereditary. The structural alterations of both forms occur on the short arm of chromosome 3 (3p).</p>
        <p>Families at high risk for developing renal cancer were studied, which led to the cloning of genes. The genes whose alteration resulted in RCC formation were tumor suppressors (VHL, TSC) or oncogenes (MET).</p>
      </sec>
      <sec id="article-28343.s5" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Subtypes of renal cell cancer include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Clear cell- most common and contains a cytoplasm rich in glycogen and lipids. This subtype is likely to be associated with 3p deletion.</p>
          </list-item>
          <list-item>
            <p>Chromophilic masses are often bilateral and be associated with trisomy 7/17</p>
          </list-item>
          <list-item>
            <p>Chromophobic lesions have large polygonal cells but rarely have 3p deletion</p>
          </list-item>
          <list-item>
            <p>Oncocytoma&#x000a0;lesions have predominance of eosinophilic cells but rarely exhibit any chromosomal defects. These lesions are least likely to spread</p>
          </list-item>
          <list-item>
            <p>Collecting duct are very aggressive, occur in young people and often present with advanced disease</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-28343.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>In the early stages, when the mass is small (less than 3 centimeters), renal cell cancer is typically asymptomatic. Approximately 25% of patients are asymptomatic, and the solid renal mass is an incidental finding during a routine radiological study.</p>
        <p>As the mass grows, symptoms may include hematuria, back pain, flank mass, fatigue, weight loss, anemia, fever, and/or high serum calcium level.</p>
        <p>The classic clinical triad of flank pain, hematuria, and flank mass is not common, presenting in only 10% of patients. When this classic triad is present, it usually indicates advanced disease.</p>
      </sec>
      <sec id="article-28343.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>A urine test may show hematuria. Urine analysis may detect cancer cells in the urine. A blood test may show anemia or high serum calcium levels.<xref ref-type="bibr" rid="article-28343.r7">[7]</xref><xref ref-type="bibr" rid="article-28343.r8">[8]</xref></p>
        <p>If RCC is suspected, renal and bladder ultrasound is usually the first radiographic test. If the renal ultrasound shows a solid mass or a complex cyst with septations or nodules, the next test should be a dedicated CT scan of the kidneys, ureters, and bladder before and after IV contrast with delayed imaging of the entire abdomen and pelvis.</p>
        <p>If the renal ultrasound is negative, but the patient has unexplained hematuria, a CT scan before and after IV contrast should be the next test as small solid renal masses can be easily missed on ultrasound and small renal stones also can be missed on ultrasound.</p>
        <p>On CT scan, RCC will typically demonstrate significant enhancement; usually, greater than 20 Hounsfield units (HU), more after contrast. Typically, postcontrast HU of renal cancer measure about 141 HU. The subtypes papillary cell and clear cell may enhance less than RCC.</p>
        <p>CT scan is used to stage RCC. CT scan will detect lymphadenopathy and invasion to the renal vein or inferior vena cava or invasion to adjacent organs. CT scan can detect metastatic disease to the bones of the abdomen and pelvis only. Whole body bone scan is the test of choice to detect bone metastases. Chest CT scan also should be obtained, as RCC presents with lung metastases in about 10% to 20%. The use of PET-CT is controversial but is helpful for distant metastases.</p>
        <p>Abdominal MRI is just as good as CT scan for diagnosing and staging RCC but is more subject to limitations such as respiratory motion artifact because the images take longer to acquire.</p>
      </sec>
      <sec id="article-28343.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Treatment depends on the stage of the tumor. See staging."</p>
        <list list-type="bullet">
          <list-item>
            <p>For stage&#x000a0;I renal cell cancer measuring less than 7 centimeters and confined to the kidney, nephrectomy or partial nephrectomy is the treatment of choice and is usually curative. Radiofrequency ablation or cryotherapy is an option in patients with bilateral tumors and small cortical tumors. Imaging surveillance is an option in elderly patients with a short life expectancy who are not good surgical candidates, as many renal cell cancers are slow growing.</p>
          </list-item>
          <list-item>
            <p>For stage II renal cell cancer, laparoscopic radical nephrectomy is the treatment of choice.</p>
          </list-item>
          <list-item>
            <p>For stage III renal cell cancer, open radical nephrectomy is the standard of care. Adrenalectomy or extensive lymph node dissection is only recommended when abdominal CT shows evidence of adrenal or lymph node invasion.</p>
          </list-item>
          <list-item>
            <p>Stage IV renal cell cancer is not curable. Treatment is palliative. Treatment may include tumor embolization, external-beam radiation therapy, and nephrectomy, but these treatments are not aimed at cure, rather prolonged survival and palliation. Immunotherapy and chemotherapy can prolong survival.&#x000a0;Drugs that may be used to&#x000a0;reduce the risk of complications from bone metastases include bisphosphonates and Xgeva.<xref ref-type="bibr" rid="article-28343.r9">[9]</xref><xref ref-type="bibr" rid="article-28343.r10">[10]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-28343.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnosis of other solid renal tumors includes&#x000a0;the following: renal oncocytoma, lipid-poor renal angiomyolipoma, renal metastases, renal lymphoma, solitary fibrous tumor (very rare), and multilocular cystic nephroma.</p>
        <p>Other renal abnormalities that can mimic RCC include&#x000a0;the following: a prominent column of Bertin, renal abscess, renal infarct, and complex renal cyst.&#x000a0;</p>
        <p>The finding of a prominent column of Bertin is typically a questionable ultrasound finding which requires cross-sectional imaging CT scan or MRI to confirm.&#x000a0;</p>
        <p>The finding of renal access typically has other clinical findings to support such as pyelonephritis, high white blood cell (WBC) count, fever, and chills.</p>
        <p>The finding of renal infarct is usually associated with vascular abnormalities such as renal vein thrombosis or trauma related.</p>
        <p>To differentiate a complex renal cyst from renal cell cancer, radiologists use the Bosniak classification.</p>
      </sec>
      <sec id="article-28343.s10" sec-type="Staging">
        <title>Staging</title>
        <p>Below is the Robson staging for RCC; although it has largely&#x000a0;been replaced by the TNM staging which is much more complicated.</p>
        <p>Robson staging:</p>
        <list list-type="bullet">
          <list-item>
            <p>Stage I:&#x000a0;limited to kidney</p>
          </list-item>
          <list-item>
            <p>Stage II:&#x000a0;involvement of perinephric fat but remains limited to&#x000a0;Gerota's fascia</p>
          </list-item>
          <list-item>
            <p>Stage III</p>
          </list-item>
          <list-item>
            <p>IIIa:&#x000a0;renal vein involvement</p>
          </list-item>
          <list-item>
            <p>IIIb:&#x000a0;nodal involvement</p>
          </list-item>
          <list-item>
            <p>IIIc:&#x000a0;both IIIa and IIIb</p>
          </list-item>
          <list-item>
            <p>Stage IV</p>
          </list-item>
          <list-item>
            <p>IVa:&#x000a0;direct invasion of adjacent organs/structures</p>
          </list-item>
          <list-item>
            <p>IVb:&#x000a0;distant metastases</p>
          </list-item>
        </list>
        <p>TNM staging (seventh edition)</p>
        <list list-type="bullet">
          <list-item>
            <p>T1</p>
          </list-item>
          <list-item>
            <p>T1a:&#x000a0;limited to kidney, greater than 4 cm</p>
          </list-item>
          <list-item>
            <p>T1b:&#x000a0;limited to kidney, greater than 4 cm but less than 7 cm</p>
          </list-item>
          <list-item>
            <p>T2:&#x000a0;limited to kidney, greater than 7 cm</p>
          </list-item>
          <list-item>
            <p>T2a:&#x000a0;limited to kidney, greater than 7 cm but not more than 10 cm</p>
          </list-item>
          <list-item>
            <p>T2b:&#x000a0;limited to kidney, greater than 10 cm</p>
          </list-item>
          <list-item>
            <p>T3:&#x000a0;tumor/tumor thrombus extension into major veins or perinephric tissues but not into ipsilateral adrenal gland or beyond the Gerota fascia</p>
          </list-item>
          <list-item>
            <p>T3a:&#x000a0;spread to renal vein</p>
          </list-item>
          <list-item>
            <p>T3b:&#x000a0;spread to infra-diaphragmatic IVC</p>
          </list-item>
          <list-item>
            <p>T3c:&#x000a0;spread to supradiaphragmatic IVC or invades the wall of the IVC</p>
          </list-item>
          <list-item>
            <p>T4:&#x000a0;involves ipsilateral adrenal gland or invades beyond&#x000a0;Gerota's fascia</p>
          </list-item>
          <list-item>
            <p>N0:&#x000a0;no nodal involvement</p>
          </list-item>
          <list-item>
            <p>N1:&#x000a0;metastatic involvement of regional lymph node/sM</p>
          </list-item>
          <list-item>
            <p>M0:&#x000a0;no distant metastases</p>
          </list-item>
          <list-item>
            <p>M1:&#x000a0;distant metastasesStage groupings</p>
          </list-item>
          <list-item>
            <p>Stage I:&#x000a0;T1 N0 M0</p>
          </list-item>
          <list-item>
            <p>Stage II:&#x000a0;T2 N0 M0</p>
          </list-item>
          <list-item>
            <p>Stage III:&#x000a0;T3 or N1 with M0</p>
          </list-item>
          <list-item>
            <p>Stage IV:&#x000a0;T4 or M1</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-28343.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis depends on stage on histology of the cell type.</p>
        <list list-type="bullet">
          <list-item>
            <p>Stage 1 has a 90% 5-year survival rate.</p>
          </list-item>
          <list-item>
            <p>Stage 2 has a 50% 5-year survival rate.</p>
          </list-item>
          <list-item>
            <p>Stage 3 gas a 30&#x000a0;% 5-year survival rate.</p>
          </list-item>
          <list-item>
            <p>Sagte 4 has a 5% 5-year survival rate.</p>
          </list-item>
        </list>
        <p>Papillary&#x000a0;RCC has the best 5-year survival rate, 90%. Clear cell cancer subtype has second-best 5-year survival, 70%.</p>
      </sec>
      <sec id="article-28343.s12" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Evidence-based approach to renal cell cancer</p>
        <p>Renal cell cancer is relatively common in the US and often presents with nonspecific signs and symptoms. The malignancy is ideally&#x000a0;managed with an interprofessional team that includes a urologist, nephrologist, oncologist, and a geneticist. Over the past two decades, the mortality rates from this malignancy have dropped because of earlier detection and treatment. five-year survival for stage 1 cancer is greater than 90% and 79% for stage 2 renal cancer. For those with lymph node involvement, the survival drops to less than 40% over five years. Factors associated with improved survival include obesity, good performance status, complete excision of the primary and a long disease-free&#x000a0;interval from the time of surgery to the presence of&#x000a0;metastases. Patients with a family history should be educated about the need for other members of the family to undergo screening. Patients at high risk for renal cell cancer should also be educated about the signs and symptoms; as earlier the cancer is managed, the better the prognosis.<xref ref-type="bibr" rid="article-28343.r11">[11]</xref><xref ref-type="bibr" rid="article-28343.r12">[12]</xref> (Level V)</p>
      </sec>
      <sec id="article-28343.s13">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=28343&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=28343">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/cancer/renal-cell-cancer/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=28343">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/28343/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=28343">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-28343.s14">
        <fig id="article-28343.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Abdomen CT, Bosniak IV Left Renal Cell Lesion Consistent With Renal Cell Carcinoma Contributed by Scott Dulebohn, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="bosniak__IV__left__renal__cell__carcinoma" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-28343.s15">
        <fig id="article-28343.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Histology, Pathology, Histopathology of renal cell adenocarcinoma kidney, Cancer, Neoplasms, Kidney Diseases Contributed by Dr. Edwin P. Ewing Jr., The Centers for Disease Control and Prevention (CDC)</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="20G0035_lores" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-28343.s16">
        <fig id="article-28343.image.f3" position="float" orientation="portrait">
          <caption>
            <p>Gross Pathology of Bisected Kidney, Large Renal Cell Carcinoma, Tumor tissu, Renal cortex, Neoplasms Contributed by Dr. Edwin P. Ewing Jr., The Centers for Disease Control and Prevention (CDC)</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="20G0029_lores" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-28343.s17">
        <title>References</title>
        <ref id="article-28343.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kuroda</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sugawara</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kusano</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yuba</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yorita</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Takeuchi</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>A review of&#x000a0;ALK-rearranged renal cell carcinomas with a&#x000a0;focus on clinical and pathobiological aspects.</article-title>
            <source>Pol J Pathol</source>
            <year>2018</year>
            <volume>69</volume>
            <issue>2</issue>
            <fpage>109</fpage>
            <page-range>109-113</page-range>
            <pub-id pub-id-type="pmid">30351856</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28343.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gr&#x000fc;nwald</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>[Risk-adapted (immuno)therapy for renal cell carcinoma].</article-title>
            <source>Urologe A</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>57</volume>
            <issue>11</issue>
            <fpage>1326</fpage>
            <page-range>1326-1333</page-range>
            <pub-id pub-id-type="pmid">30350129</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28343.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ding</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Ge</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Xia</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>The E2F1-miR-520/372/373-SPOP Axis Modulates Progression of Renal Carcinoma.</article-title>
            <source>Cancer Res</source>
            <year>2018</year>
            <month>Dec</month>
            <day>15</day>
            <volume>78</volume>
            <issue>24</issue>
            <fpage>6771</fpage>
            <page-range>6771-6784</page-range>
            <pub-id pub-id-type="pmid">30348808</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28343.r4">
          <label>4</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>van Leeuwaarde</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Ahmad</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>van Nesselrooij</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Zandee</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Giles</surname>
                <given-names>RH</given-names>
              </name>
            </person-group>
            <chapter-title>Von Hippel-Lindau Syndrome</chapter-title>
            <person-group person-group-type="editor">
              <name>
                <surname>Adam</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mirzaa</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Pagon</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Amemiya</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <source>GeneReviews<sup>&#x000ae;</sup> [Internet]</source>
            <publisher-name>University of Washington, Seattle</publisher-name>
            <publisher-loc>Seattle (WA)</publisher-loc>
            <year>2000</year>
            <month>5</month>
            <day>17</day>
            <pub-id pub-id-type="pmid">20301636</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28343.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ganguly</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chandra</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chatterjee</surname>
                <given-names>IB</given-names>
              </name>
            </person-group>
            <article-title>Pathobiology of cigarette smoke-induced invasive cancer of the renal pelvis and its prevention by vitamin C.</article-title>
            <source>Toxicol Rep</source>
            <year>2018</year>
            <volume>5</volume>
            <fpage>1002</fpage>
            <page-range>1002-1010</page-range>
            <pub-id pub-id-type="pmid">30338226</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28343.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Capitanio</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Bensalah</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bex</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Boorjian</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Bray</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Coleman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gore</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wood</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Russo</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology of Renal Cell Carcinoma.</article-title>
            <source>Eur Urol</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>75</volume>
            <issue>1</issue>
            <fpage>74</fpage>
            <page-range>74-84</page-range>
            <pub-id pub-id-type="pmid">30243799</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28343.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ward</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Tanaka</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Campbell</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Remer</surname>
                <given-names>EM</given-names>
              </name>
            </person-group>
            <article-title>2017 AUA Renal Mass and Localized Renal Cancer Guidelines: Imaging Implications.</article-title>
            <source>Radiographics</source>
            <year>2018</year>
            <season>Nov-Dec</season>
            <volume>38</volume>
            <issue>7</issue>
            <fpage>2021</fpage>
            <page-range>2021-2033</page-range>
            <pub-id pub-id-type="pmid">30339517</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28343.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liaw</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Winoker</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Mehrazin</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Imaging Protocols for Active Surveillance in Renal Cell Carcinoma.</article-title>
            <source>Curr Urol Rep</source>
            <year>2018</year>
            <month>Aug</month>
            <day>13</day>
            <volume>19</volume>
            <issue>10</issue>
            <fpage>81</fpage>
            <pub-id pub-id-type="pmid">30105557</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28343.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jonasch</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Updates to the Management of Kidney Cancer.</article-title>
            <source>J Natl Compr Canc Netw</source>
            <year>2018</year>
            <month>May</month>
            <volume>16</volume>
            <issue>5S</issue>
            <fpage>639</fpage>
            <page-range>639-641</page-range>
            <pub-id pub-id-type="pmid">29784745</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28343.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dabestani</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Marconi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kuusk</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Bex</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Follow-up after curative treatment of localised renal cell carcinoma.</article-title>
            <source>World J Urol</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>36</volume>
            <issue>12</issue>
            <fpage>1953</fpage>
            <page-range>1953-1959</page-range>
            <pub-id pub-id-type="pmid">29767327</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28343.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rolley</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Aubert</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Baize</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bigot</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>[Management of metastatic renal cell carcinomass].</article-title>
            <source>Prog Urol</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>28</volume>
            <issue>14</issue>
            <fpage>777</fpage>
            <page-range>777-782</page-range>
            <pub-id pub-id-type="pmid">30174169</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28343.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Joshi</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Handorf</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Zibelman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Plimack</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Uzzo</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Kutikov</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Smaldone</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Geynisman</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Treatment Facility Volume and Survival in Patients with Metastatic Renal Cell Carcinoma: A Registry-based Analysis.</article-title>
            <source>Eur Urol</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>74</volume>
            <issue>3</issue>
            <fpage>387</fpage>
            <page-range>387-393</page-range>
            <pub-id pub-id-type="pmid">29880274</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
